Core Viewpoint - Bank of America Securities reaffirms "Buy" rating for MicroPort Medical (00853) due to attractive risk-reward profile and diversified high-value consumables product portfolio [1] Group 1: Business Growth Potential - The surgical robotics segment is expected to be a key growth driver, contributing 19% of total revenue by 2034 [1] - The company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1] Group 2: Financial Projections - Total revenue forecasts for 2026 to 2034 have been raised by 0.1% to 1.5% [1] - Target price has been increased from HKD 16.8 to HKD 17 [1] Group 3: Shareholder Support - Shareholder Shanghai Industrial Group is expected to provide financial and operational support and will focus on improving the company's governance structure [1]
美银证券：微升微创医疗(00853)目标价至17港元 重申“买入”评级